Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 1

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 1
---
 directors, I would like to express our appreciation for your interest in Denali.

Sincerely,

Ryan J. Watts, Ph.D.

President and Chief Executive Officer

#### DENALI THERAPEUTICS INC.

#### 161 Oyster Point Blvd.

#### South San Francisco, California 94080

### NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
| Time and Date     
 Place             |     | June 3, 2025 at 10:00 a.m. Pacific Time                                                                                                                                                                                                                                                                                                                                                                                                                                
 The Annual Meeting will be a completely virtual meeting of stockholders to be conducted via live webcast. You will be able to attend the virtual Annual Meeting by accessing www.virtualshareholdermeeting.com/DNLI2025. You will need the 16-digit control number found on your Notice of Internet Availability, your proxy card or on the instructions that accompany your proxy materials to participate in the Annual Meeting and vote your shares electronically. |
|:------------------|:----|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Items of Business |     | •To elect three directors from the nominees described in this proxy statement.                                                                                                                                                                                                                                                                                                                                                                                         
 •To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for fiscal year endingDecember 31, 2025.                                                                                                                                                                                                                                                                                                                            
 •To approve, on an advisory basis, executive compensation.                                                                                                                                                                                                                                                                                                                                                                                                             
 •To transact other business that may properly come before the Annual Meeting.                                                                                                                                                                                                                                                                                                                                                                                          |
| Record Date       |     | April 9, 2025 (the “Record Date”). Only stockholders of record at the close of business on the Record Date are entitled to receive notice of, and to vote at, the Annual Meeting.                                                                                                                                                                                                                                                                                      |

On or about April 17, 2025, we expect to mail to our stockholders a Notice of Internet Availability of Proxy Materials (the "Notice") containing instructions on how to access our proxy statement for our annual meeting and our annual report to stockholders, which will be available on our website at https://denalitherapeutics.com/investors in the SEC Filings section of our Investor & Media Relations web page. The Notice, our proxy statement and annual report to stockholders can also be accessed directly at the following website: www.proxyvote.com.

Your Vote Is Important. Whether or not you plan to attend the virtual Annual Meeting, we encourage you to submit your vote via the Internet, telephone or mail as soon as possible to ensure your